Phase 3 Sickle Cell Clinical Trials
11 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–11 of 11 trials
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Sickle Cell Disease
Novartis Pharmaceuticals354 enrolled32 locationsNCT06439082
Recruiting
Phase 3
Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease
Vaso-Occlusive Pain Episode in Sickle Cell Disease
Nantes University Hospital104 enrolled11 locationsNCT07274254
Recruiting
Phase 3
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
Sickle Cell Disease
Sanofi192 enrolled53 locationsNCT06975865
Recruiting
Phase 3
Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease
Sickle Cell DiseaseAcute Chest Syndrome
Assistance Publique - Hôpitaux de Paris130 enrolled1 locationNCT06818266
Recruiting
Phase 3
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Sickle Cell Disease
Novo Nordisk A/S408 enrolled174 locationsNCT06612268
Recruiting
Phase 3
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Sickle Cell DiseaseThalassemia
Novo Nordisk A/S480 enrolled105 locationsNCT06609226
Recruiting
Phase 3
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
Sickle Cell Disease
Sanofi100 enrolled7 locationsNCT07247188
Recruiting
Phase 2Phase 3
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
Sickle Cell Disease
Pfizer389 enrolled49 locationsNCT05431088
Recruiting
Phase 3
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
Beta-ThalassemiaSickle Cell DiseaseHematologic Diseases+4 more
Vertex Pharmaceuticals Incorporated26 enrolled6 locationsNCT05477563
Recruiting
Phase 3
Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa
Sickle Cell DiseaseSickle Cell Anemia in Children
Brown University400 enrolled1 locationNCT05285917
Recruiting
Phase 3
RElated Haplo-DonoR Haematopoietic stEm Cell Transplantation for Adults With Severe Sickle Cell Disease
Sickle Cell Disease
King's College Hospital NHS Trust120 enrolled1 locationNCT05392894